|Year : 2018 | Volume
| Issue : 4 | Page : 120-123
Sulfonylurea and neuroprotection: The bright side of the moon
Nawar R Hussien1, Marwa S Al-Naimi1, Huda A Rasheed1, Hayder M Al-kuraishy2, Ali I Al-Gareeb2
1 Department of Clinical Pharmacology, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq
2 Department of Clinical Pharmacology and Therapeutic, Medical Faculty, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq
|Date of Web Publication||10-Dec-2018|
Dr. Hayder M Al-kuraishy
Department of Pharmacology, Toxicology and Medicine, College of Medicine, Al-Mustansiriya University, PO Box 14132, Baghdad
Source of Support: None, Conflict of Interest: None
Sulfonylurea (SUR) agents are the second and most used oral hypoglycemic drugs after metformin and they still as an imperative tool for most favorable of glucose control. SURs are used mainly in the management of Type 2 diabetes mellitus since; they are effective in the glycemic control and reduction of microvascular complications. First-generation SUR represents 3% of used oral hypoglycemic agents while second and third generations are used in about 25% in patients with Type 2 diabetes mellitus. Upregulation of SUR1 receptor has been observed after stroke and traumatic brain injury, therefore, SUR such as glibenclamide inhibits brain edema and astrocyte swelling following brain insults. SUR drugs mainly glibenclamide is effective at a low dose in the management of cerebral stroke and could be a contestant with corticosteroid in controlling brain edema.
Keywords: Sulfonylurea, stroke, type 2 diabetes mellitus
|How to cite this article:|
Hussien NR, Al-Naimi MS, Rasheed HA, Al-kuraishy HM, Al-Gareeb AI. Sulfonylurea and neuroprotection: The bright side of the moon. J Adv Pharm Technol Res 2018;9:120-3
|How to cite this URL:|
Hussien NR, Al-Naimi MS, Rasheed HA, Al-kuraishy HM, Al-Gareeb AI. Sulfonylurea and neuroprotection: The bright side of the moon. J Adv Pharm Technol Res [serial online] 2018 [cited 2022 Aug 8];9:120-3. Available from: https://www.japtr.org/text.asp?2018/9/4/120/247174
| Introduction|| |
Sulfonylurea (SUR) agents are the second and most used oral hypoglycemic drugs after metformin, and they still as an imperative tool for most favorable of glucose control. SUR drugs have pancreatic and extra-pancreatic effects in the regulation of blood glucose through stimulation the release of insulin from pancreatic β-cells, inhibition of glucagon release, and reduction of hepatic insulin clearance. Uses of SUR drugs have much pros and cons in the clinical practice such as weight gains, hypoglycemia, and cardiovascular outcomes; thus, their safety and clinical benefit have been a matter of debate.
SUR is used mainly in the management of Type 2 diabetes mellitus since; they are effective in the glycemic control and reduction of microvascular complications. The first-generation SUR represents 3% of used oral hypoglycemic agents while second and third generations are used in about 25% in patients with Type 2 diabetes mellitus.,
SUR receptors are the molecular target of SUR drugs; there are three types of these receptors which are SUR1, SUR2A, and SUR2B.
The main function of these receptors is to sense the intracellular levels of adenosine triphosphate (ATP) and adenosine diphosphate in response to the potassium channels, thus, KATP channel and nonselective cation channel (NCCa-ATP) observes and sense the intracellular energy balance.
High glucose levels increase the production of ATP which triggers the closure of KATP channel causing change in the pancreatic β-cell membrane potential that activates the opening of ca-channel leading to insulin exocytosis.
Upregulation of SUR1 receptor has been observed after stroke and traumatic brain injury in rats, therefore, SUR drugs such as glibenclamide inhibits brain edema and astrocyte swelling following brain insults.
Moreover, animal modeled study illustrated an over-expression of SUR1 receptor in ammonia cultured astrocyte and the cortical neurons after induced hepatic encephalopathy while treatment with glibenclamide reveres these pathological changes, these findings proposed the neuroprotective effect of SUR.
Glibenclamide produces dose-independent reduction in brain edema induced by neuronal damage since; glibenclamide at a dose of 2 mg/kg or 5 mg/kg illustrated insignificant differences on brain edema in rats due to inhibition of neuronal-specific K-Cl cotransporter.
Cerebral ischemia activates the release of hypoxia-inducible factor 1/2 which plays a crucial role in up-regulation of SUR1 receptor, also neuronal damage induced by cerebral ischemia provokes the stimulation of protein and mitogen-activated protein kinases which are involved in the acceleration of SUR1 receptor currents and subsequent KATP and NCCa-ATP channels.
Moreover, Kurland et al., study illustrated that SUR1 receptors are linked with transient receptor potential melastatin 4(Trpm4) which plays an important role in the progression of brain edema, damage of blood–brain barriers and neuronal death. Up-regulated Trpm4 protein remains about 1 month after cerebral infarction; therefore, a pharmacological inhibition of these channels by SUR drugs may reduce the complications of cerebral infarction.
Normally, SUR drugs such as glibenclamide not accumulated in the neurons under normal physiological condition but during stroke, penetration of SUR drugs are enhanced due to breakdown of blood–brain barrier and neuronal acidic PH as well as selective trapping of SUR drugs in the ischemic areas, thus glibenclamide is mainly accumulated in the injured but not in the normal neurons.
Recently, glibenclamide has a new attention due to its pleiotropic effects; it inhibits Sur1-regulated NCCa-ATP channel leading to anti-inflammatory effects and activation of neurogenesis which per se ameliorate cerebral stroke, spinal cord injury, premature encephalopathy, and traumatic brain injury.
Therefore, glibenclamide intravenous formulation has been developed for the management of acute brain injury since; uses of glibenclamide in this context are highly promising due to the improvement of stroke outcomes in many animal model studies.,
In addition, recombinant tissue plasminogen activator which is approved by FDA for ischemic stroke is associated with risk of bleeding due to activation of matrix metalloproteinase 9 (MMP9). Glibenclamide inhibits MMP9 activation, therefore, a combination of glibenclamide with tissue plasminogen activator improves stroke outcomes.
The neuroprotective effect of glibenclamide may be beyond SUR1 blocking effect as supported by Ortega et al., study that demonstrated a potential blocking effect of glibenclamide on microglial KATP channel leading to augmentation of microglia phagocytic activity with modulation of proinflammatory cytokines release and then reduction of neuronal loss and necrosis.
Preclinical study by Simard et al., disclosed that glibenclamide improves stroke score and outcomes after ischemic stroke with significant amelioration in the cognitive and sensory-motor performances due to activation of cortical and hippocampal angiogenesis.
In this context, most of the previous and current studies focused on the glibenclamide as a prototype SUR drug, but recent meta-analysis study confirmed that second and third generations SUR are safe and effective neuroprotective agents as glibenclamide in attenuation of cerebral stroke complications.
Recently, Douros et al., study illustrated differences in the cardiometabolic and risk of neurological complications from different SUR drugs, short-acting SUR such as gliclazide and glipizide are associated with a high risk of stroke while long-acting such as glimepiride and glibenclamide reduce the risk of stroke and neurological complications.
On the other hand, Monami et al. observational study reported that the uses of SURs are associated with an increase in the cardiovascular complications and stroke risk due to interfering with cardiac ATP-sensitive k-channels leading to cardiac dysfunction and arrhythmias.
As well, a systematic meta-analysis study done by Liu et al. disclosed that diabetic patients treated with SUR are at high risk of stroke compared to the other oral hypoglycemic drugs.
It has been mentioned by many researchers the link between SUR and other cardio-metabolic complications which might be falsely positive or negative conclusions since; these contradictory studies explained by short-term or observational studies.
Recently, King et al., human study confirmed the potential role of glyburide in blocking SUR1-TRPM4 which are concerned with the development of brain edema and microvascular dysfunction in patients with extensive hemispheric stroke.
A recent study disclosed that therapeutic hypothermia is efficient models of therapy in the prevention of brain edema and mortality rate during experimental cerebral stroke in rats. Glibenclamide potentiates and produced synergistic effect with therapeutic hypothermia in the prevention of stroke complications through inhibition of stroke-induced cytokine releases.
Previously, Darsalia et al. disclosed that glimepiride was effective in stroke prevention in normal but not in diabetic mice through augmentation of insulin levels which has a neuroprotective effect, therefore, this drug is ineffective in prevention of stroke initiation and complications compared to linagliptin drug.
Thus, the estimation of individual drug of SUR group is recommended to clarify the molecular differences at neuronal activity.
Therefore, from previous and extensive studies, SUR drugs mainly glibenclamide is effective at a low dose in the management of cerebral strokes and could be a contestant with corticosteroid in controlling brain edema.
| Conclusion|| |
SUR is effective in the management of cerebral strokes and could be a contestant with corticosteroid in controlling brain edema.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Thulé PM, Umpierrez G. Sulfonylureas: A new look at old therapy. Curr Diab Rep 2014;14:473.
Leonard CE, Brensinger CM, Aquilante CL, Bilker WB, Boudreau DM, Deo R, et al.
Comparative safety of sulfonylureas and the risk of sudden cardiac arrest and ventricular arrhythmia. Diabetes Care 2018;41:713-22.
Kontopantelis E, Springate DA, Reeves D, Ashcroft DM, Rutter MK, Buchan I, et al.
Glucose, blood pressure and cholesterol levels and their relationships to clinical outcomes in type 2 diabetes: A retrospective cohort study. Diabetologia 2015;58:505-18.
Al-Kuraishy HM, Al-Gareeb AI. Erectile dysfunction and low sex drive in men with type 2 DM: The potential role of diabetic pharmacotherapy. J Clin Diagn Res 2016;10:FC21-6.
Burke MA, Mutharasan RK, Ardehali H. The sulfonylurea receptor, an atypical ATP-binding cassette protein, and its regulation of the KATP channel. Circ Res 2008;102:164-76.
Tsuda N, Kawaji A, Takagi M, Higashi C, Nakamura M, Hosaka Y, et al.
Free fatty acid receptor 1 agonist, MR1704, lowers blood glucose levels in rats unresponsive to the sulfonylurea, glibenclamide. Drug Dev Res 2018;79:16-21.
Song J, Yang Y, Mauvais-Jarvis F, Wang YP, Niu T. KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: A bioinformatics assessment. BMC Med Genet 2017;18:64.
Mehta RI, Tosun C, Ivanova S, Tsymbalyuk N, Famakin BM, Kwon MS, et al.
Sur1-trpm4 cation channel expression in human cerebral infarcts. J Neuropathol Exp Neurol 2015;74:835-49.
Kurland DB, Tosun C, Pampori A, Karimy JK, Caffes NM, Gerzanich V, et al.
Glibenclamide for the treatment of acute CNS injury. Pharmaceuticals (Basel) 2013;6:1287-303.
Delpire E, Days E, Lewis LM, Mi D, Kim K, Lindsley CW, et al.
Small-molecule screen identifies inhibitors of the neuronal K-cl cotransporter KCC2. Proc Natl Acad Sci U S A 2009;106:5383-8.
Woo SK, Kwon MS, Geng Z, Chen Z, Ivanov A, Bhatta S, et al.
Sequential activation of hypoxia-inducible factor 1 and specificity protein 1 is required for hypoxia-induced transcriptional stimulation of abcc8. J Cereb Blood Flow Metab 2012;32:525-36.
Lin YF, Chai Y. Functional modulation of the ATP-sensitive potassium channel by extracellular signal-regulated kinase-mediated phosphorylation. Neuroscience 2008;152:371-80.
Kurland DB, Gerzanich V, Karimy JK, Woo SK, Vennekens R, Freichel M, et al.
The sur1-trpm4 channel regulates NOS2 transcription in TLR4-activated microglia. J Neuroinflammation 2016;13:130.
Szeto V, Chen NH, Sun HS, Feng ZP. The role of KATP
channels in cerebral ischemic stroke and diabetes. Acta Pharmacol Sin 2018;39:683-94.
Tosun C, Koltz MT, Kurland DB, Ijaz H, Gurakar M, Schwartzbauer G, et al.
The protective effect of glibenclamide in a model of hemorrhagic encephalopathy of prematurity. Brain Sci 2013;3:215-38.
Sheth KN, Elm JJ, Beslow LA, Sze GK, Kimberly WT. Glyburide advantage in malignant edema and stroke (GAMES-RP) trial: Rationale and design. Neurocrit Care 2016;24:132-9.
Wali B, Ishrat T, Atif F, Hua F, Stein DG, Sayeed I, et al.
Glibenclamide administration attenuates infarct volume, hemispheric swelling, and functional impairments following permanent focal cerebral ischemia in rats. Stroke Res Treat 2012;2012:460909.
Ortega FJ, Jolkkonen J, Mahy N, Rodríguez MJ. Glibenclamide enhances neurogenesis and improves long-term functional recovery after transient focal cerebral ischemia. J Cereb Blood Flow Metab 2013;33:356-64.
Simard JM, Popovich PG, Tsymbalyuk O, Gerzanich V. Spinal cord injury with unilateral versus bilateral primary hemorrhage – Effects of glibenclamide. Exp Neurol 2012;233:829-35.
Caffes N, Kurland DB, Gerzanich V, Simard JM. Glibenclamide for the treatment of ischemic and hemorrhagic stroke. Int J Mol Sci 2015;16:4973-84.
Douros A, Yin H, Yu OH, Filion KB, Azoulay L, Suissa S. Pharmacologic differences of sulfonylureas and the risk of adverse cardiovascular and hypoglycemic events. Diabetes Care 2017;40:1506-13.
Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: A meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;15:938-53.
Liu R, Wang H, Xu B, Chen W, Turlova E, Dong N, et al.
Cerebrovascular safety of sulfonylureas: The role of KATP channels in neuroprotection and the risk of stroke in patients with type 2 diabetes. Diabetes 2016;65:2795-809.
Varvaki Rados D, Catani Pinto L, Reck Remonti L, Bauermann Leitão C, Gross JL. The association between sulfonylurea use and all-cause and cardiovascular mortality: A meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med 2016;13:e1001992.
King ZA, Sheth KN, Kimberly WT, Simard JM. Profile of intravenous glyburide for the prevention of cerebral edema following large hemispheric infarction: Evidence to date. Drug Des Devel Ther 2018;12:2539-52.
Zhu S, Gao X, Huang K, Gu Y, Hu Y, Wu Y, et al.
Glibenclamide enhances the therapeutic benefits of early hypothermia after severe stroke in rats. Aging Dis 2018;9:685-95.
Darsalia V, Ortsäter H, Olverling A, Darlöf E, Wolbert P, Nyström T, et al.
The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: A comparison with glimepiride. Diabetes 2013;62:1289-96.
|This article has been cited by|
||Glimepiride mitigates tauopathy and neuroinflammation in P301S transgenic mice: role of AKT/GSK3ß signaling
| ||Mennatallah O. Zaki, S. El-Desouky, Doaa A. Elsherbiny, Mohamed Salama, Samar S. Azab |
| ||Inflammopharmacology. 2022; |
|[Pubmed] | [DOI]|
||Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study
| ||Geert Jan Biessels,Chloë Verhagen,Jolien Janssen,Esther van den Berg,Gudrun Wallenstein,Bernard Zinman,Mark A. Espeland,Odd Erik Johansen |
| ||Diabetologia. 2021; |
|[Pubmed] | [DOI]|
||Common NLRP3 inflammasome inhibitors and Covid-19: Divide and Conquer
| ||Gaber El-Saber Batiha, Dr. Ali I. Al-Gareeb, Safaa Qusti, Eida M. Alshammari, Damilare Rotimi, Oluyomi Stephen Adeyemi, Hayder M. Al-kuraishy |
| ||Scientific African. 2021; : e01084 |
|[Pubmed] | [DOI]|
||COVID-19 in Relation to Hyperglycemia and Diabetes Mellitus
| ||Hayder M. Al-kuraishy,Ali I. Al-Gareeb,M. Alblihed,Susana G. Guerreiro,Natália Cruz-Martins,Gaber El-Saber Batiha |
| ||Frontiers in Cardiovascular Medicine. 2021; 8 |
|[Pubmed] | [DOI]|
||Current Therapies for Neonatal Hypoxic–Ischaemic and Infection-Sensitised Hypoxic–Ischaemic Brain Damage
| ||Konstantina Tetorou,Claudia Sisa,Arzo Iqbal,Kim Dhillon,Mariya Hristova |
| ||Frontiers in Synaptic Neuroscience. 2021; 13 |
|[Pubmed] | [DOI]|
||Cardiac myxoma as a potential trigger of takotsubo cardiomyopathy: A brief review on mechanistic and clinical perspectives
| ||Kenan Yalta,Ugur Ozkan,Tülin Yalta,Ertan Yetkin |
| ||Monaldi Archives for Chest Disease. 2021; |
|[Pubmed] | [DOI]|
||Neuroprotective Effects of Diabetes Drugs for the Treatment of Neonatal Hypoxia-Ischemia Encephalopathy
| ||Laura Poupon-Bejuit,Eridan Rocha-Ferreira,Claire Thornton,Henrik Hagberg,Ahad A. Rahim |
| ||Frontiers in Cellular Neuroscience. 2020; 14 |
|[Pubmed] | [DOI]|
||Takotsubo cardiomyopathy: an obscure cause of emerging cardiovascular manifestations in the setting of Bickerstaff’s brainstem encephalitis
| ||Kenan Yalta,Ertan Yetkin,Tulin Yalta |
| ||Neurological Sciences. 2020; |
|[Pubmed] | [DOI]|
||Neuromodulatory effects of anti-diabetes medications: a mechanistic review
| ||Habib Yaribeygi,Milad Ashrafizadeh,Neil C. Henney,Thozhukat Sathyapalan,Tannaz Jamialahmadi,Amirhossein Sahebkar |
| ||Pharmacological Research. 2019; : 104611 |
|[Pubmed] | [DOI]|